Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts

• Curium Biopharma will continue to lead discovery and new product development
• Strategic move aims to accelerate biopharma innovation and revolutionize the diagnosis and treatment of cancer
• Curium International headquarters remain in Paris, France, while the United States headquarters are in St Louis, Missouri

(St Louis, Missouri – 17 November, 2025) Curium, a company dedicated to using cutting edge technology and innovative science in nuclear medicine to diagnose and treat millions of patients with cancer, announced today it is evolving into a new phase of discovery to revolutionize cancer treatment for patients.  To accelerate biopharma innovation, Curium has set up their global headquarters in Boston, Massachusetts and has launched a new Business Unit, Curium Biopharma, to lead discovery and new product development.  Curium is also expanding manufacturing capacity in Maryland Heights, Missouri and Noblesville, Indiana.  Onshoring the manufacturing of our new therapeutic and diagnostic products is critical to reliably serving our customers and patients throughout North America.

Boston, considered to be the global biotech hub, is strategically located between Curium’s manufacturing sites in the United States (U.S.) and Europe.  Also home to top-tier academic institutions and leaders in scientific innovations, Boston naturally provides a pool of talent across disciplines critical to Curium’s success.  Curium’s central Boston headquarters is a global innovation center, think tank and immersive learning lab with high-tech workspaces designed to stimulate and support forward thinking.

Renaud Dehareng, CEO Curium Group, says “Curium is at the forefront of a new revolution in cancer treatment.  As we amplify our focus on new product development, setting up our headquarters in Boston allows us to be closer to innovative science and technology, as well as access to important industry resources.  Combined with the exceptional talent we attract, this creates an ideal foundation to support our ambition to improve the lives of millions of patients with cancer.”

Chaitanya Tatineni, CEO Curium Biopharma, says “To position Curium for the future, Curium Biopharma will be dedicated to building our pipeline of innovative diagnostics and therapeutic assets through internal development and strategic acquisitions or partnerships, to bring the next generation of products to patients.  It’s a truly exciting time to be working in oncology and nuclear medicine”.